TRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial
- Conditions
- Aortic Stenosis, Severe
- Interventions
- Procedure: TAVI WITHOUT ON-SITE SURGERYProcedure: TAVI WITH ON-SITE SURGERY
- Registration Number
- NCT05751577
- Lead Sponsor
- Azienda Usl di Bologna
- Brief Summary
The primary efficacy objective is to determine whether a TAVI procedure performed by experienced operators in centers without on-site cardiac surgery is noninferior to TAVI procedure performed by the same operators in centers with on-site cardiac surgery in terms of all-cause death, stroke and rehospitalization for cardiovascular cause. The primary safety objective is to demonstrate that mortality associated with periprocedural complications actionable by emergent cardiac surgery did not differ between study arms.
- Detailed Description
TRACS is an all-comer, prospective, randomized, multicenter, open-label trial with blinded adjudicated evaluation of outcomes (PROBE). The TRACS trial will involve centers without on-site cardiac surgery, but with experienced operators already performing TAVI at the referring center with on-site cardiac surgery. Thus, participating centers and their study TAVI operators must follow selective criteria for eligibility. Participants will be recruited after Heart Team indication to TAVI procedure. The eligibility of each single patient to the study MUST BE CONFIRMED and VALIDATED by unanimous decision of the Heart Team. Study patients will be randomized in a 2:1 fashion to TAVI procedure performed by the same experienced operators either in the center without on-site cardiac surgery or in the referring center with on-site cardiac surgery.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 566
- Severe aortic stenosis
- Indication to TAVI confirmed by the Study Heart Team
AND one of the following:
- Inoperable due to prohibitive operative risk
- High surgical risk as defined as STS score >8%
The presence of at least one clinical factor that, by unanimous judgment of the Study Heart Team, compromises the benefit/risk ratio in the case of emergent cardiac surgery:
- Porcelain aorta or severely atherosclerotic aorta
- Frailty/Reduced physical performance
- Cognitive impairment, dementia, or Parkinson's disease
- Severe liver disease/cirrhosis
- Hostile chest
- Internal mammalian artery or other critical conduit(s) crossing midline and/or adhering to the posterior table of the sternum
- Severe pulmonary hypertension and/or severe right ventricular dysfunction
- Severe Chronic Obstructive Pulmonary Disease (COPD)
- Age ≥85 years
- Unsuitable for transfemoral TAVI
- Emergent TAVI
- Noncardiovascular comorbidity reducing life expectancy to <1 year
- Any factor precluding 1-year follow-up
- Refusal informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description EXPERIMENTAL ARM: TAVI WITHOUT ON-SITE SURGERY TAVI WITHOUT ON-SITE SURGERY After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery CONTROL ARM: TAVI WITH ON-SITE SURGERY TAVI WITH ON-SITE SURGERY After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
- Primary Outcome Measures
Name Time Method Primary safety endpoint 1-year To test whether mortality due to periprocedural complications actionable by emergent cardiac surgery differs between the TAVI procedures performed in the center without on-site cardiac surgery and the TAVI procedures performed by the same team in the center with on-site cardiac surgery
Primary efficacy endpoint 1-year 1-year cumulative occurrence of all-cause death, stroke and hospital readmission for CV cause To test if the outcome of TAVI procedures performed by experienced operators in the center without onsite cardiac surgery is non inferior to that of TAVI procedures performed by the same team in the center with on-site cardiac surgery
- Secondary Outcome Measures
Name Time Method Secondary efficacy endpoints 1-year All-cause death Cardiovascular death Myocardial infarction Hospital admission for cardiovascular cause Hospital admission for heart failure Cerebrovascular accident Ischemic stroke Hospital admission for pneumonia (± respiratory failure) Need for balloon aortic valvuloplasty for emergent condition Quality of life measured with the Eq-5D and KCCQ-12 scales Time spent on the waiting list before TAVI
Other safety endpoints 1-year Cardiac tamponade Bleeding Kidney failure (requirement for renal replacement therapy) Severe aortic regurgitation (aortic regurgitation according to current guidelines) Multiorgan failure (failure of at least two organ systems) Vascular access site and access related complications Conduction disturbances and arrhythmias Endocarditis Valve thrombosis Valve malpositioning Valve embolization Ectopic valve deployment TAV-in-TAV deployment
Trial Locations
- Locations (9)
Azienda Ospedaliero Universitaria di Ferrara
🇮🇹Ferrara, Italy
Ospedale Guglielmo da Saliceto di Piacenza
🇮🇹Piacenza, Italy
Ospedale Misericordia di Grosseto
🇮🇹Grosseto, Italy
Ospedale degli Infermi di Biella
🇮🇹Biella, Italy
Ospedale San Donato di Arezzo
🇮🇹Arezzo, Italy
Ospedale Cardinal Massaia di Asti
🇮🇹Asti, Italy
Azienda Unità Sanitaria Locale
🇮🇹Bologna, Italy
Azienda ULSS 3 Serenissima, Ospedale di Mirano
🇮🇹Mirano, Italy
Azienda Ospedaliera di Reggio Emilia
🇮🇹Reggio Emilia, Italy